[1]曾文宏,叶芳芳,周志明.哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察[J].医学信息,2022,35(23):140-142.[doi:10.3969/j.issn.1006-1959.2022.23.029]
　ZENG Wen-hong,YE Fang-fang,ZHOU Zhi-ming.Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis[J].Journal of Medical Information,2022,35(23):140-142.[doi:10.3969/j.issn.1006-1959.2022.23.029]
点击复制

哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
140-142
栏目:
药物与临床
出版日期:
2022-12-01

文章信息/Info

Title:
Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis
文章编号:
1006-1959（2022）23-0140-04
作者:
曾文宏; 叶芳芳; 周志明
（吉水县人民医院呼吸内科，江西 吉水 331600）
Author(s):
ZENG Wen-hong; YE Fang-fang; ZHOU Zhi-ming
(Department of Respiratory,Jishui County People’s Hospital,Jishui 331600,Jiangxi,China)
关键词:
慢性支气管炎; 左氧氟沙星; 哌拉西林钠他唑巴坦钠; 肺功能
Keywords:
Chronic bronchitis; Levofloxacin; Piperacillin sodium and tazobactam sodium; Pulmonary function
分类号:
R562.2+1
DOI:
10.3969/j.issn.1006-1959.2022.23.029
文献标志码:
A
摘要:
目的 观察哌拉西林钠他唑巴坦钠（PS/TS）联合左氧氟沙星治疗慢性支气管炎（CB）的临床疗效及安全性。方法 选取2019年1月-2021年5月吉水县人民医院收治的68例CB患者为研究对象，按照随机数字表法分为对照组与观察组，各34例。对照组给予PS/TS治疗，观察组在其基础上加用左氧氟沙星治疗，比较两组临床疗效、症状缓解时间、肺功能[呼气流量峰值（PEF）、最大通气量（MVV）、第1 s用力呼气量（FEV1）]、实验室指标[白细胞（WBC）、中性粒细胞百分比（NEUT）、C反应蛋白（CRP）]、不良反应。结果 观察组治疗有效率较对照组高（P＜0.05）；观察组症状（咳嗽、咳痰、喘息）缓解时间短于对照组（P＜0.05）；两组治疗后PEF、MVV、FEV1均有所升高，且观察组较对照组高（P＜0.05）；两组治疗后WBC、NEUT、CRP水平均有所下降，且观察组较对照组低（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 PS/TS联合左氧氟沙星治疗CB效果确切，可缩短症状缓解时间，改善患者肺功能及实验室指标，且不良反应少。
Abstract:
Objective To observe the clinical efficacy and safety of piperacillin sodium and tazobactam sodium (PS/TS) combined with levofloxacin in the treatment of chronic bronchitis (CB).Methods A total of 68 CB patients admitted to Jishui County People’s Hospital from January 2019 to May 2021 were selected as the research objects and divided into control group and observation group according to the random number table method, with 34 cases in each group. The control group was treated with PS/TS, and the observation group was treated with levofloxacin on the basis of the control group. The clinical efficacy, symptom relief time, pulmonary function [peak expiratory flow (PEF), maximum ventilation (MVV), forced expiratory volume in one second (FEV1)], laboratory indexes [white blood cell (WBC), neutrophil percentage (NEUT), C-reactive protein (CRP)] and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group was higher than that in the control group (P<0.05). The remission time of symptoms (cough, sputum, wheezing) in the observation group was shorter than that in the control group (P<0.05). PEF, MVV and FEV1 increased in both groups after treatment, and the observation group was higher than the control group (P<0.05). The levels of WBC, NEUT and CRP in the two groups decreased after treatment, and the levels in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion PS/TS combined with levofloxacin is effective in the treatment of CB, which can shorten the time of symptom relief, improve the lung function and laboratory indexes of patients, and has fewer adverse reactions.

参考文献/References:

[1]武金银.莫西沙星对慢性支气管炎急性发作期血气指标、内皮素-1等炎性因子水平的影响[J].安徽医药,2019,23(1):176-179.[2]孙玲,是若春,杨欣颖.哌拉西林钠舒巴坦钠联合左氧氟沙星对老年社区获得性肺炎治疗效果及炎症标志物的影响[J].中国药物与临床,2021,21(5):822-824.[3]谢丽平,马彦辉.左氧氟沙星联合阿奇霉素治疗慢性支气管炎对患者血清致炎因子水平及肺功能的影响[J].临床医学,2020,40(8):88-90.[4]Viola A,Ferrazzano L,Martelli G,et al.Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin/tazobactam stability stud[J].Eur J Pharm Sci,2019,136:104957.[5]冯永,赵辉,白秋江,等.哌拉西林钠舒巴坦钠联合阿奇霉素治疗慢性阻塞性肺疾病急性加重的临床观察[J].中国煤炭工业医学杂志,2017,20(8):894-896.[6]宫薇,王文华.莫西沙星、左氧氟沙星和环丙沙星治疗下呼吸道感染的疗效及成本效果及药学评价[J].中国农村卫生,2020,12(15):71,73.[7]白植宽.左氧氟沙星联合哌拉西林钠/他唑巴坦钠对支气管扩张症铜绿假单胞菌急性感染者的疗效评估[J].中国微生态学杂志,2018,30(5):560-563.[8]中华医学会呼吸病学分会哮喘学组.上－下气道慢性炎症性疾病联合诊疗与管理专家共识[J].中华医学杂志,2017,97(26):2001-2022.[9]迟岩,怀丽梅,赵鑫亮.老年慢性支气管炎呼吸道感染病原菌分布特点[J].中国病原生物学杂志,2016,11(12):1137-1139,1143.[10]叶晓兰,叶强,张国兵,等.基于肾功能情况的左氧氟沙星合理用药分析[J].中国现代应用药学,2019,36(7):855-858.[11]翁书彪.注射用哌拉西林钠他唑巴坦钠治疗小儿支气管肺炎疗效观察[J].中国医药导刊,2017,19(9):934-936.[12]朱选风,高兆芳,刘剑南,等.治疗急性气管支气管炎致剧烈咳嗽的抗菌药物选用及疗效[J].西北药学杂志,2019,34(5):657-660.[13]Downes KJ,Cowden C,Laskin BL,et al.Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children[J].JAMA Pediatr,2017,171(12):e173219.[14]杨宇杰,陈大兴,潘华峰,等.阿奇霉素干混悬剂联合左氧氟沙星氯化钠注射液治疗慢性支气管炎及对TNF-α、IL-6的影响[J].广东医学,2019,40(6):834-837.[15]王刚,焦成建.左氧氟沙星联合氨溴索对慢性支气管炎患者的疗效及免疫功能水平的影响[J].实用临床医药杂志,2019,23(7):76-79[16]王建,王紫汀,朱莉,等.支气管扩张感染患者行哌拉西林钠他唑巴坦联合依替米星治疗的临床效果与安全性分析[J].中国病案,2018,19(8):96-98.[17]张怡,朱鹏,董玮.左氧氟沙星与头孢哌酮舒巴坦对老年社区获得性下呼吸道感染的疗效及其对患者炎性因子水平的影响[J].贵州医药,2017,41(10):1046-1048.[18]王秀云,余金十.注射用哌拉西林钠/舒巴坦钠与注射用哌拉西林钠/他唑巴坦钠治疗重度医院获得性肺炎的成本-效果分析[J].世界临床药物,2016,37(12):835-839.[19]张炜刚.左氧氟沙星氯化钠注射液联合阿奇霉素治疗慢性支气管炎的效果观察[J].中国药物与临床,2020,20(7):1152-1154.

相似文献/References:

[1]李秀杰.含左氧氟沙星化疗方案治疗耐利福平结核病的预后分析[J].医学信息,2019,32(02):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
　LI Xiu-jie.Prognosis Analysis of Levofloxacin-containing Chemotherapy for Rifampicin-resistant Tuberculosis[J].Journal of Medical Information,2019,32(23):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
[2]冯瑞丰.阿奇霉素治疗急性细菌性下呼吸道感染的 有效性和安全性评价[J].医学信息,2019,32(11):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
　FENG Rui-feng.Evaluation of the Efficacy and Safety of Azithromycin in the Treatment of Acute Bacterial Lower Respiratory Tract Infections[J].Journal of Medical Information,2019,32(23):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
[3]隋文峰,潘 雪.左氧氟沙星联合头孢哌酮舒巴坦治疗老年肺炎的疗效及其对肺功能的影响[J].医学信息,2020,33(06):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
　SUI Wen-feng,PAN Xue.Effect of Levofloxacin Combined with Cefoperazone Sulbactam in the Treatment of Senile Pneumonia and Its Effect on Lung Function[J].Journal of Medical Information,2020,33(23):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
[4]李 萍.需要层次理论在慢性支气管炎健康指导中的作用[J].医学信息,2020,33(12):172.[doi:10.3969/j.issn.1006-1959.2020.12.057]
　LI Ping.The Role of Need Level Theory in the Health Guidance of Chronic Bronchitis[J].Journal of Medical Information,2020,33(23):172.[doi:10.3969/j.issn.1006-1959.2020.12.057]
[5]张春霞,徐世红.小青龙汤联合三子养亲汤治疗慢性支气管炎患者的临床效果及对呼吸功能的影响[J].医学信息,2021,34(07):164.[doi:10.3969/j.issn.1006-1959.2021.07.047]
　ZHANG Chun-xia,XU Shi-hong.Clinical Effect of Xiaoqinglong Decoction Combined with Sanzi Yangqin Decoction in the Treatment of Patients with Chronic Bronchitis and Its Influence on Respiratory Function[J].Journal of Medical Information,2021,34(23):164.[doi:10.3969/j.issn.1006-1959.2021.07.047]
[6]陈 嫈.左氧氟沙星致上消化道出血再发2例报道[J].医学信息,2021,34(08):192.[doi:10.3969/j.issn.1006-1959.2021.08.054]
[7]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2021,34(23):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[8]谢艳红,冯 莉.左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响[J].医学信息,2021,34(16):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
　XIE Yan-hong,FENG Li.Effect of Levofloxacin on Serum IL-6 and IFN-γ Levels in Elderly Patients with Pulmonary Tuberculosis[J].Journal of Medical Information,2021,34(23):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
[9]谢艳红.左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者的效果[J].医学信息,2021,34(17):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]
　XIE Yan-hong.The Effect of Levofloxacin Combined with Rifapentine Capsule in the Treatment of Pulmonary Tuberculosis in the Elderly[J].Journal of Medical Information,2021,34(23):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]
[10]张 翠,王 喆,杨悦杰,等.利福平联合多西环素及左氧氟沙星治疗布氏菌病的疗效[J].医学信息,2022,35(03):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]
　ZHANG Cui,WANG Zhe,YANG Yue-jie,et al.Effect of Rifampicin Combined with Doxycycline and Levofloxacin in the Treatment of Brucellosis[J].Journal of Medical Information,2022,35(23):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]

更新日期/Last Update: 1900-01-01